Ding T, Wang S, Yang B, Li J. Biological removal of pharmaceuticals by Navicula sp. and biotransformation of bezafibrate. Chemosphere. 2020;240:124949 pubmed publisher

Majeed Y, Upadhyay R, Alhousseiny S, Taha T, Musthak A, Shaheen Y, et al. Potent and PPARα-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro. Sci Rep. 2019;9:6316 pubmed publisher

Ribeiro A, Pedrosa M, Moreira N, Pereira M, Silva A. Environmental friendly method for urban wastewater monitoring of micropollutants defined in the Directive 2013/39/EU and Decision 2015/495/EU. J Chromatogr A. 2015;1418:140-9 pubmed publisher

Southam A, Khanim F, Hayden R, Constantinou J, Koczula K, Michell R, et al. Drug Redeployment to Kill Leukemia and Lymphoma Cells by Disrupting SCD1-Mediated Synthesis of Monounsaturated Fatty Acids. Cancer Res. 2015;75:2530-40 pubmed publisher

Núñez M, Borrull F, Fontanals N, Pocurull E. Determination of pharmaceuticals in bivalves using QuEChERS extraction and liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2015;407:3841-9 pubmed publisher

Olsen R, Mary Sinclair M, Yin Z, Freeman K. Antagonizing Bcl-2 family members sensitizes neuroblastoma and Ewing's sarcoma to an inhibitor of glutamine metabolism. PLoS ONE. 2015;10:e0116998 pubmed publisher

Miller T, McEneff G, Brown R, Owen S, Bury N, Barron L. Pharmaceuticals in the freshwater invertebrate, Gammarus pulex, determined using pulverised liquid extraction, solid phase extraction and liquid chromatography-tandem mass spectrometry. Sci Total Environ. 2015;511:153-60 pubmed publisher

Takahashi H, Goto T, Yamazaki Y, Kamakari K, Hirata M, Suzuki H, et al. Metabolomics reveal 1-palmitoyl lysophosphatidylcholine production by peroxisome proliferator-activated receptor α. J Lipid Res. 2015;56:254-65 pubmed publisher

Creusot N, Brion F, Piccini B, Budzinski H, Porcher J, Aït Aïssa S. BFCOD activity in fish cell lines and zebrafish embryos and its modulation by chemical ligands of human aryl hydrocarbon and nuclear receptors. Environ Sci Pollut Res Int. 2015;22:16393-404 pubmed publisher

Lukas J, Pockrandt A, Seemann S, Sharif M, Runge F, Pohlers S, et al. Enzyme enhancers for the treatment of Fabry and Pompe disease. Mol Ther. 2015;23:456-64 pubmed publisher

Cai M, Wang R, Feng L, Zhang L. Determination of selected pharmaceuticals in tap water and drinking water treatment plant by high-performance liquid chromatography-triple quadrupole mass spectrometer in Beijing, China. Environ Sci Pollut Res Int. 2015;22:1854-67 pubmed publisher

Gao Y, Su Y, Huo Y, Mi J, Wang X, Wang Z, et al. Identification of antihyperlipidemic constituents from the roots of Rubia yunnanensis Diels. J Ethnopharmacol. 2014;155:1315-21 pubmed publisher

Zhou Z, Jiang J. Treatment of selected pharmaceuticals by ferrate(VI): performance, kinetic studies and identification of oxidation products. J Pharm Biomed Anal. 2015;106:37-45 pubmed publisher

Marsoni M, de Mattia F, Labra M, Bruno A, Bracale M, Vannini C. Uptake and effects of a mixture of widely used therapeutic drugs in Eruca sativa L. and Zea mays L. plants. Ecotoxicol Environ Saf. 2014;108:52-7 pubmed publisher

Ferguson L, Most D, Blednov Y, Harris R. PPAR agonists regulate brain gene expression: relationship to their effects on ethanol consumption. Neuropharmacology. 2014;86:397-407 pubmed publisher

Ackerman Z, Skarzinski G, Grozovski M, Oron Herman M, Sela B. Effects of antihypertensive and triglyceride-lowering agents on hepatic copper concentrations in rats with fatty liver disease. Basic Clin Pharmacol Toxicol. 2014;115:545-51 pubmed publisher

Tanoue R, Nomiyama K, Nakamura H, Hayashi T, Kim J, Isobe T, et al. Simultaneous determination of polar pharmaceuticals and personal care products in biological organs and tissues. J Chromatogr A. 2014;1355:193-205 pubmed publisher

Martin J, Santos J, Aparicio I, Alonso E. Pharmaceutically active compounds in sludge stabilization treatments: anaerobic and aerobic digestion, wastewater stabilization ponds and composting. Sci Total Environ. 2015;503-504:97-104 pubmed publisher

Yasuno T, Osafune K, Sakurai H, Asaka I, Tanaka A, Yamaguchi S, et al. Functional analysis of iPSC-derived myocytes from a patient with carnitine palmitoyltransferase II deficiency. Biochem Biophys Res Commun. 2014;448:175-81 pubmed publisher

Eisen A, Benderly M, Behar S, Goldbourt U, Haim M. Inflammation and future risk of symptomatic heart failure in patients with stable coronary artery disease. Am Heart J. 2014;167:707-14 pubmed publisher

Li X, Jiang H, Qu L, Yao W, Cai H, Chen L, et al. Hepatocyte nuclear factor 4? and downstream secreted phospholipase A2 GXIIB regulate production of infectious hepatitis C virus. J Virol. 2014;88:612-27 pubmed publisher

Tang Y, Li X, Xu Z, Guo Q, Hong C, Bing Y. Removal of naproxen and bezafibrate by activated sludge under aerobic conditions: kinetics and effect of substrates. Biotechnol Appl Biochem. 2014;61:333-41 pubmed publisher

Pucer A, Brglez V, Payre C, Pungercar J, Lambeau G, Petan T. Group X secreted phospholipase A(2) induces lipid droplet formation and prolongs breast cancer cell survival. Mol Cancer. 2013;12:111 pubmed publisher

Petrescu A, McIntosh A, Storey S, Huang H, Martin G, Landrock D, et al. High glucose potentiates L-FABP mediated fibrate induction of PPAR? in mouse hepatocytes. Biochim Biophys Acta. 2013;1831:1412-25 pubmed publisher

Schmilovitz Weiss H, Hochhauser E, Cohen M, Chepurko Y, Yitzhaki S, Grossman E, et al. Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease--a historical prospective. Lipids Health Dis. 2013;12:41 pubmed publisher

van de Weijer T, Havekes B, Bilet L, Hoeks J, Sparks L, Bosma M, et al. Effects of bezafibrate treatment in a patient and a carrier with mutations in the PNPLA2 gene, causing neutral lipid storage disease with myopathy. Circ Res. 2013;112:e51-4 pubmed publisher

Maity S, Kar D, De K, Chander V, Bandyopadhyay A. Hyperthyroidism causes cardiac dysfunction by mitochondrial impairment and energy depletion. J Endocrinol. 2013;217:215-28 pubmed publisher

Tanaka A. [Management of PBC cases failing to respond to UDCA]. Nihon Shokakibyo Gakkai Zasshi. 2013;110:16-21 pubmed

de Vries R, Dikkeschei B, Sluiter W, Dallinga Thie G, Van Tol A, Dullaart R. Statin and fibrate combination does not additionally lower plasma cholesteryl ester transfer in type 2 diabetes mellitus. Clin Lab. 2012;58:1231-9 pubmed

Ardila J, Sartori E, Rocha Filho R, Fatibello Filho O. Square-wave voltammetric determination of bezafibrate in pharmaceutical formulations using a cathodically pretreated boron-doped diamond electrode. Talanta. 2013;103:201-6 pubmed publisher

Ghonem N, Boyer J. Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come. Hepatology. 2013;57:1691-3 pubmed publisher

Tenenbaum A, Fisman E. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?. Cardiovasc Diabetol. 2012;11:140 pubmed publisher

Reverberi M, Punelli M, Smith C, Zjalic S, Scarpari M, Scala V, et al. How peroxisomes affect aflatoxin biosynthesis in Aspergillus flavus. PLoS ONE. 2012;7:e48097 pubmed publisher

Bandgar B, Sarangdhar R, Fruthous K, Mookkan J, Chaudhary S, Chavan H, et al. Synthesis and biological evaluation of ester prodrugs of Benzafibrate as orally active hypolipidemic agents. Eur J Med Chem. 2012;57:217-24 pubmed publisher

Marguerite V, Gkikopoulou E, Alberto J, Gueant J, Merten M. Phospholipase D activation mediates cobalamin-induced downregulation of Multidrug Resistance-1 gene and increase in sensitivity to vinblastine in HepG2 cells. Int J Biochem Cell Biol. 2013;45:213-20 pubmed publisher

Dou X, Li S, Wang Z, Gu D, Shen C, Yao T, et al. Inhibition of NF-?B activation by 4-hydroxynonenal contributes to liver injury in a mouse model of alcoholic liver disease. Am J Pathol. 2012;181:1702-10 pubmed publisher

Yamazaki T, Wakabayashi M, Ikeda E, Tanaka S, Sakamoto T, Mitsumoto A, et al. Induction of 1-acylglycerophosphocholine acyltransferase genes by fibrates in the liver of rats. Biol Pharm Bull. 2012;35:1509-15 pubmed

Nemoto H, Kamiya M, Nakamoto A, Matsushita T, Matsumura K, Hattori H, et al. Synthesis of highly water-soluble fibrate derivatives via BGLation. Bioorg Med Chem Lett. 2012;22:6425-8 pubmed publisher

Dillon L, Hida A, Garcia S, Prolla T, Moraes C. Long-term bezafibrate treatment improves skin and spleen phenotypes of the mtDNA mutator mouse. PLoS ONE. 2012;7:e44335 pubmed publisher

Dumont M, Stack C, Elipenahli C, Jainuddin S, Gerges M, Starkova N, et al. Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice. Hum Mol Genet. 2012;21:5091-105 pubmed publisher

Engelen M, Tran L, Ofman R, Brennecke J, Moser A, Dijkstra I, et al. Bezafibrate for X-linked adrenoleukodystrophy. PLoS ONE. 2012;7:e41013 pubmed publisher

Honda A, Ikegami T, Nakamuta M, Miyazaki T, Iwamoto J, Hirayama T, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology. 2013;57:1931-41 pubmed publisher

Constantinides A, de Vries R, van Leeuwen J, Gautier T, van Pelt L, Tselepis A, et al. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity. Eur J Intern Med. 2012;23:633-8 pubmed publisher

Krysiak R, Okopien B. Hemostatic effects of omega-3 fatty acids in isolated hypertriglyceridemic patients treated with bezafibrate. Eur J Intern Med. 2012;23:e168-9 pubmed publisher

Krysiak R, Gdula Dymek A, Okopien B. Lymphocyte-suppressing effects of omega-3 fatty acids in bezafibrate-treated patients with isolated hypertriglyceridemia. Eur J Intern Med. 2012;23:e166-7 pubmed publisher

Krysiak R, Gdula Dymek A, Okopien B. Omega-3 fatty acids enhance monocyte-suppressing effect of bezafibrate in patients with isolated hypertriglyceridemia. Eur J Intern Med. 2012;23:e171-2 pubmed publisher

Yamaguchi S, Li H, Purevsuren J, Yamada K, Furui M, Takahashi T, et al. Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders: evaluation by in vitro probe acylcarnitine assay. Mol Genet Metab. 2012;107:87-91 pubmed publisher

Fuijkschot J, Theelen T, Seyger M, van der Graaf M, de Groot I, Wevers R, et al. Sjögren-Larsson syndrome in clinical practice. J Inherit Metab Dis. 2012;35:955-62 pubmed publisher

Rudic J, Poropat G, Krstic M, Bjelakovic G, Gluud C. Bezafibrate for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;1:CD009145 pubmed publisher

Goldenberg I, Benderly M, Goldbourt U. Update on the use of fibrates: focus on bezafibrate. Vasc Health Risk Manag. 2008;4:131-41 pubmed

Sugie M, Kuriki A, Arai D, Ichikawa H, Kawamura M. [A case report of acute neuromyopathy induced by concomitant use of colchicine and bezafibrate]. No To Shinkei. 2005;57:785-90 pubmed

Tenenbaum A, Motro M, Fisman E. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol. 2005;4:14 pubmed

Manfredi R, Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J Infect. 2001;42:181-8 pubmed

Yoshino G, Hirano T, Kazumi T. [BECAIT [Bezafibrate Coronary Atherosclerosis Intervention Trial]]. Nihon Rinsho. 2001;59 Suppl 3:433-5 pubmed

Ericsson C. Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress. Eur Heart J. 1998;19 Suppl H:H37-41 pubmed

de Faire U, Ericsson C, Grip L, Nilsson J, Svane B, Hamsten A. Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials. Cardiovasc Drugs Ther. 1997;11 Suppl 1:257-63 pubmed

Goa K, Barradell L, Plosker G. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia. Drugs. 1996;52:725-53 pubmed

de Faire U, Ericsson C, Grip L, Nilsson J, Svane B, Hamsten A. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Eur Heart J. 1996;17 Suppl F:37-42 pubmed

Poyart C, Marden M, Kister J. Bezafibrate derivatives as potent effectors of hemoglobin. Methods Enzymol. 1994;232:496-513 pubmed

Monk J, Todd P. Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs. 1987;33:539-76 pubmed

Stahlberg D, Reihner E, Ewerth S, Einarsson K, Angelin B. Effects of bezafibrate on hepatic cholesterol metabolism. Eur J Clin Pharmacol. 1991;40 Suppl 1:S33-6 pubmed

Kanterewicz E, Sanmarti R, Riba J, Trias I, Autonell J, Brugues J. Bezafibrate induced rhabdomyolysis. Ann Rheum Dis. 1992;51:536-8 pubmed